Jasper Therapeutics COO reports new option holdings
Jasper Therapeutics’ Chief Operating Officer Matthew E. Ros reports initial derivative holdings tied to Kira Pharmaceuticals’ merger into a Jasper subsidiary.
Rhea-AI Filing Summary
Jasper Therapeutics’ Chief Operating Officer Matthew E. Ros reports initial derivative holdings tied to Kira Pharmaceuticals’ merger into a Jasper subsidiary. He holds options to buy 103,204 shares of Jasper voting common stock at $0.0100 per share and options linked to 92,278 shares of non-voting convertible preferred stock at $0.6100 per share, received in exchange for 622,456 former Kira options and vesting monthly over 48 months. Each preferred share is automatically convertible into 61 voting common shares after stockholder approval of the conversion, subject to a beneficial ownership cap between 4.9% and 19.9%.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Ros Matthew E
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1, F2, F3 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F1, F2, F3, F4 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 103,204 contracts (Direct);
Stock Options (Right to Buy) — 92,278 contracts (Direct)
Footnotes (4)
- F1. Pursuant to the Agreement and Plan of Merger by and among Kira Pharmaceuticals ("Kira"), Jasper Therapeutics, Inc. ("Jasper") and Kira Holdco Inc. ("Merger Sub"), a wholly owned subsidiary of Jasper, dated July 16, 2026 (the "Merger Agreement"), Kira merged with and into Merger Sub, with Merger Sub surviving (the "Merger"). Each option to purchase shares of Kira ordinary shares (each, a "Kira Option") that was outstanding and unexercised immediately prior to the closing of the Merger, whether or not vested, was converted into and became an option to purchase Jasper's voting common stock, par value $0.0001 per share ("Voting Common Stock") and shares of the Jasper Non-Voting Convertible Preferred Stock, par value $0.0001 ("Preferred Stock") pursuant to the terms and conditions of the Merger Agreement.
- F2. Beginning on June 7, 2026, the option vests in equal monthly installments over 48 months, subject to the Reporting Person's continued service to Issuer through each vesting date.
- F3. Pursuant to the Merger Agreement, the Reporting Person received 103, 204 options to purchase shares of Voting Common Stock and 92,278 options to purchase shares of Preferred Stock in exchange for 622,456 Kira Options.
- F4. On the third business day following the receipt of stockholder approval of the conversion of the Preferred Stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's Voting Common Stock, subject to certain limitations, including that a holder of Preferred Stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date.
Key Figures
Voting common stock options: 103,204 shares
Non-voting preferred stock options: 92,278 shares
Exchanged Kira options: 622,456 options
+3 more
6 metrics
Voting common stock options
103,204 shares
Options to purchase Jasper voting common stock at $0.0100 per share
Non-voting preferred stock options
92,278 shares
Options to purchase Jasper Non Voting Convertible Preferred Stock at $0.6100 per share
Exchanged Kira options
622,456 options
Former Kira options exchanged for Jasper options under the Merger Agreement
Vesting period
48 months
Options vest in equal monthly installments beginning June 7, 2026
Preferred conversion ratio
61
Each Preferred Stock share converts into 61 Voting Common Stock shares after stockholder approval
Beneficial ownership cap range
4.9%–19.9%
Holder may set a cap on beneficial ownership when converting Preferred Stock
Key Terms
Agreement and Plan of Merger, Non Voting Convertible Preferred Stock, par value, beneficially own
4 terms
Agreement and Plan of Merger regulatory
"Pursuant to the Agreement and Plan of Merger by and among Kira Pharmaceuticals..."
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Non Voting Convertible Preferred Stock financial
"...shares of the Jasper Non-Voting Convertible Preferred Stock, par value $0.0001..."
par value financial
"...Voting Common Stock, par value $0.0001 per share..."
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
beneficially own regulatory
"...would beneficially own more than a specified percentage..."
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider holdings did Jasper Therapeutics (JSPR) COO Matthew Ros report?
Matthew E. Ros reported options over 103,204 Jasper voting common shares at $0.0100 per share and options linked to 92,278 non-voting convertible preferred shares at $0.6100 per share, all held directly after the Kira Pharmaceuticals merger.
How were Matthew Ros’s options in Jasper Therapeutics (JSPR) created from the Kira merger?
Under the Kira–Jasper merger agreement, Matthew Ros received 103,204 voting common stock options and 92,278 preferred stock options in exchange for 622,456 Kira options, preserving his economic position through newly issued Jasper derivative securities.
What are the vesting terms of Matthew Ros’s options at Jasper Therapeutics (JSPR)?
Beginning on June 7, 2026, Matthew Ros’s options vest in equal monthly installments over 48 months, conditioned on his continued service to Jasper Therapeutics through each vesting date, which spreads his ability to exercise these options over four years.
How does Jasper Therapeutics (JSPR) preferred stock held via options convert into common shares?
Each share of Jasper non-voting convertible preferred stock is automatically convertible into 61 voting common shares on the third business day after stockholder approval of the conversion, subject to limits on how much the holder may beneficially own.
What beneficial ownership limits apply to converting Jasper Therapeutics (JSPR) preferred stock?
Upon conversion, a preferred holder cannot beneficially own more than a chosen cap between 4.9% and 19.9% of Jasper’s voting common stock outstanding, restricting how many common shares can be received in any conversion event.
Does Jasper Therapeutics (JSPR) preferred stock reported by Matthew Ros expire?
The non-voting convertible preferred stock referenced in Matthew Ros’s option holdings has no expiration date, meaning the preferred shares, once issued, remain outstanding unless converted or otherwise disposed of under their terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
